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Xuejie Wu and Feng Xu*Abstract
Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that play a crucial role in both innate and adaptive
immune responses. DCs orient the immune responses by modulating the balance between protective immunity to
pathogens and tolerance to self-antigens. Staphylococcus aureus (S. aureus) is a common member of human skin
microbiota and can cause severe infections with significant morbidity and mortality. Protective immunity to
pathogens by DCs is required for clearance of S. aureus. DCs sense the presence of the staphylococcal components
using pattern recognition receptors (PRRs) and then orchestrate immune systems to resolve infections. This review
summarizes the possible roles of DCs, in particular their Toll-like receptors (TLRs) involved in S. aureus infection and
strategies by which the pathogen affects activation and function of DCs.
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Dendritic cells (DCs) were first identified by Steinman
and colleagues in the early 1970s. The nomenclature was
originally based on the cell? s stellate shape and membran-
ous processes [1]. DCs are now recognized as one of the
most potent and efficient professional APCs within the
immune system [2]. They have the unique capacity to
prime na?ve T cell-mediated protective immune responses
as well as maintain tolerance to self-antigens by control-
ling antigen presentation to T cells [3]. Upon antigen
uptake and exposure to appropriate proinflammatory
signals or cellular stress, DCs generally migrate from the
tissue to secondary lymphoid organs and differentiate
into mature DCs which are characterized by upregula-
tion of major histocompatibility complex (MHC) class I
and II, adhesins and costimulatory molecules. Here,
they process and present captured antigens in the pres-
ence of the correct costimulatory molecules to initiate
antigen-specific T and B cell immune responses [4,5].
DCs also participate in inducing and maintaining periph-
eral immune tolerance in the steady state, possibly
through the induction of T-cell anergy or T regulatory
cells (Tregs) via self-antigen presentation [6,7].* Correspondence: xufeng99@yahoo.com
Department of Infectious Diseases, Second Affiliated Hospital, Zhejiang
University School of Medicine, Hangzhou 310009, China
? 2014 Wu and Xu; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.In the past decades, huge efforts have been made to
explore the myriad immune functions of DCs after the
pioneering work initiated by Steinman and colleagues. It is
now well known that the DCs represent a heterogeneous
cell population with distinctive functions and subsets [8].
Generally, human and mouse DCs can be grouped into
at least two subsets, referred to as conventional DCs
(cDCs) and plasmacytoid DCs (pDCs) based on differing
morphological, phenotypic and functional specificity.
cDCs can be further subdivided into two main subsets
according to their phenotype, functional specialization,
specific gene expression program and transcription factors
[9-11]. These subdivisions correlate to the large and differ-
ing roles that DCs have on every aspect of the immune
system, and will be described in detail below.
S. aureus is a common member of human skin micro-
biota and is well habituated to the human host [12,13].
This pathogen can cause infections of nearly all tissues
and organs, and staphylococcal disease can vary in severity
ranging from skin and soft tissue infections to necrotizing
fasciitis, pneumonia, endocarditis, sepsis, and toxic shock
syndrome. The high pathogenecity of S. aureus depends
on its numerous tactics to evade immune system [14-17].
At present, infection of methicillin-resistant S. aureus
(MRSA) which is resistant to most of the current available
potent antibiotics poses a serious public health threat
[18,19]. MRSA was previously confined to hospital settingsis is an Open Access article distributed under the terms of the Creative
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chance to make contact with this bacterium is very high
[20]. However, community acquired MRSA (CA-MRSA)
has emerged soon and gained much attention by clinicians
and investigators [16,21].
DCs sense the presence of pathogens using pattern
recognition receptors (PRRs), which recognize pathogen
associated molecular patterns (PAMPs) expressed by vari-
ous microorganisms. TLRs are the most well described
PRRs [22]. To date, 13 different TLRs have been identified,
10 human TLRs (TLR1-10) and 12 mouse TLRs (TLR1-9,
TLR11, TLR12, TLR13). TLR10 and TLR11-13 are specific
to humans or mice respectively [23,24]. TLR 1, 2, 4-6 and
11 are expressed at the cell surface while TLR 3 and 7-9 are
located in the endosomal compartments [25]. It has
recently been shown that TLR-driven early glycolytic repro-
gramming is essential for the anabolic demands of DC acti-
vation and function [26]. TLR expression varies according
to DC subset. In humans, cDCs express TLR 1-8 and 10,
and can be activated by various bacterial products [27,28].
Conversely, human and mouse pDCs express a restricted
set of TLRs including TLR7 and TLR9 which sense viral
RNA and DNA respectively [29,30]. Several TLRs have
been implicated in the recognition of staphylococcal struc-
tures. For example, TLR2 is involved in the recognition of
staphylococcal peptidoglycan, lipoteichoic acid (LTA)
and staphylococcal enterotoxin B (SEB), while TLR4 can
be activated by leukocidin (Luk), an exotoxin of S. aureus
[31-34]. The differing TLRs of DC subsets and corre-
sponding ligands are summarized in Table 1.
This review will focus on the possible roles of DCs and
their well-equipped armamentarium, particularly TLRs in
S. aureus infection, as well as the strategies utilized by
S. aureus to evade DCs. Importantly, the findings sum-
marized here may have implications for developingTable 1 TLRs of DC subsets and corresponding ligands
DC subsets TLR ligands
cDCs 1/2 Triacyl lipoprotein







10 No ligand known
pDCs 7 ssRNA
9 unmethylated CpG motifs of DNA
10 No ligand known
Abbreviations: dsRNA, double-stranded RNA; ssRNA, single-stranded RNA.novel therapies aimed at improving DC function during S.
aureus infection.
Dendritic cell subsets and TLRs
cDCs and their TLRs
cDCs were initially thought to be of myeloid origin,
based on their expression of the myeloid markers, such
as CD13 and CD33 [35,36]. However, several studies
have shown that cDCs may also originate from lymphoid
precursor cells expressing Flt3 under the treatment of
Flt3 ligand (Flt3L), a growth factor for hemopoietic
progenitors [37-39]. Murine cDCs include both lymphoid
organ-resident DCs and migratory DCs [40]. Considering
the complexity of the cDC origin, most studies simply
categorize murine cDCs as CD11b+ or CD8α+/CD103+
cDCs. Here, CD8α+ DCs are demonstrated to be more
efficient in the cross-presentation of exogenous antigens
on MHC class I molecules [2,41]. In humans, cDCs can
be further identified as BDCA1+DCs and BDCA3+DCs
according to the characteristic surface expression of
BDCA1 (CD1c) and BDCA3 (CD141) [42-44]. Human
cDCs nearly express all TLRs except TLR9 [28,29,45,46].
Although cDCs do express TLR10, its ligands and func-
tionality are still unknown [47]. Extracellular TLRs of
cDCs such as TLR1, 2, 4-6 recognize cell wall components
of bacteria and fungi. Lipopolysaccharide (LPS), a struc-
turally diverse molecule, is a well-known ligand for TLR4
and the mechanisms involved in versatility of ligand rec-
ognition which is crucial for combating diverse microbial
infection is unraveled by TLR4-MD-2-LPS structure [48].
TLR5 activation by flagellin is important for priming of
the adaptive immune response in the intestine [49]. Ex-
cept for direct recognition of the Gram positive bacteria-
derived peptidoglycan [50], triacyl lipoprotein and diacyl
lipoprotein can also be recognized by TLR2 through the
formation of heterodimers with TLR1 or TLR6 respect-
ively [22]. This exemplifies the complexity of TLRs and
PAMPs recognition. After being activated by TLR ligands
or agonists, cDCs secrete several cytokines important in
immune responses, such as IL-6, IL-8, IL-10, IL-12 and
TNF-α [22,51]. Besides, cDCs also recognize nucleotide-
containing structures via intracellular TLRs. For example,
TLR3 recognizes virus-derived double-stranded RNA
(dsRNA) while TLR7 and TLR8 recognize single-stranded
RNA (ssRNA) which comes from bacteria, virus or self
[22,52,53].
pDCs and their TLRs
Cell surface markers of human pDCs are characterized as
CD4+CD45RA+HLA-DR+ CD123highCD11c-lineage-cells.
pDCs do not express most of the myeloid antigens, such
as CD11b, CD13, CD14, or CD33 and were suggested to
be of lymphoid origin. Human pDCs express two add-
itional markers, BDCA2 (CD303) and BDCA4 (CD304)
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pDCs may also stem from myeloid precursors expressing
Flt3 when stimulated with Flt3L [37,38]. Compared to
cDCs, both human and mouse pDCs preferentially express
high levels of TLR7 and TLR9 [29,45]. Although minimal
expression of TLR1 on the pDCs has been reported by
several studies, its biological function remains unclear
[29,47,55]. More importantly, pDCs neither express TLR2,
a heterodimeric partner for TLR1, nor respond to TLR1/
TLR2 ligands [29,45,55,56]. pDCs also express TLR10
which has been confirmed at both the mRNA and protein
level [47,55,57]. However, the biological function and ligand
of TLR10 have not been determined. pDCs preferentially
secrete type I IFNs, especially IFN-α when TLR7 and TLR9
are triggered by ssRNA and unmethylated CpG motifs of
DNA, respectively [28,29,45,55,58].
Although DCs are rare subsets of cells among all
blood mononuclear cells, they serve as a bridge linking
innate and adaptive immune responses. Current data
suggest that both cDCs and pDCs can be either myeloid
or lymphoid origin. A developmental scheme for human
DC lineages is shown in Figure 1.
Virulence factors of S. aureus
The whole genome of S. aureus encodes numerous
toxins, mainly including pore-forming toxins, exfoliative
toxins and superantigens [59]. The most common pore-
forming toxins are hemolysin-α (Hla, α-toxin), leukotoxinsFigure 1 A developmental scheme for human DC lineages. Both cDCs
categorized as two main subsets including BDCA1+DCs and BDCA3+DCs. A
progenitors; CMP, common myeloid precursors; CLP, common lymphoid pand phenol-soluble modulins (PSMs) [60,61]. Hla is re-
leased by most S. aureus clinical isolates and spontan-
eously assembles into a heptameric pore in target cell
membranes. It preferentially targets human lymphocytes
and monocytes but not neutrophils [62,63]. Leukotoxins
belong to a bicomponent family of cytotoxins consisting
of one class S and one class F protein [64]. To date, five
class F subunits (HlgB, LukF-PV, LukD, LukF? -PV, and
LukG) and six class S subunits (HlgA, HlgC, LukS-PV,
LukE, LukM, and LukH) have been reported [60]. Leuko-
toxins can lyse monocytes, macrophages, and neutrophils
via forming hetero-oligomeric pore complexes in target
cell membranes [65,66]. PSMs, including the PSMα and
PSMβ subfamilies are small, α-helical amphipathic pep-
tides which have multiple roles in staphylococcal virulence
[67,68].
Exfoliative toxins (ETs) A, B and D produced by S.
aureus can efficiently cleave a single peptide bond in the
extracellular region of human and mouse desmoglein 1
(Dsg1) [69]. The expression of ETs has been confirmed to
be regulated by accessory gene regulator (agr) [70]. ETs
are glutamate-specific serine proteases with high species
specificity and responsible for staphylococcal scalded skin
syndrome (SSSS), which predominantly affects infants and
is characterized by the loss of superficial skin layers,
dehydration, and secondary infections [71].
The staphylococcal superantigens (SAgs) are a family
of potent immunostimulatory exotoxins. At present, 23and pDCs can originate from CMP and CLP lineages. Human cDCs are
bbreviations: HSC, hemopoietic stem cell; MPP, multipotent
recursors. cDCs, conventional DCs; pDCs, plasmacytoid DCs.
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the staphylococcal enterotoxins (SEs) A, B (multiple variant
forms exist), C (multiple minor variant forms exist), D, E,
and G; the staphylococcal enterotoxin-like toxins H, I, J, K,
L, M, N, O, P, Q, R, S, T, U, V, and X and toxic shock
syndrome toxin-1 (TSST-1) [60,72,73]. Some of them can
directly cross-link MHC class II molecules on APCs with T
cell receptors to induce potent T-cell activation and
cytokine release [74,75].
Roles of different subsets of DCs in S. aureus infection
DCs are more potent in presenting small amounts of mi-
crobial superantigens such as SEA [76], B, E and TSST-1,
compared with monocytes or B cells. They also stimulate
T cell proliferation far more efficiently than monocytes or
B cells in the presence of SEA, SEB, SEE and TSST-1 [77],
all of which bind well to MHC class II molecules [78-80].
After stimulation with the S. aureus Cowan strain I, both
mouse and human DCs expressed IL-12 p40 and p35
mRNA. More importantly, they also produced IL-12p70
protein, a crucial factor for induction of Th1 immune
response [81]. The S. aureus Cowan I strain, when
cultured with epidermal DCs from the skin, also known
as Langerhans cells (LCs), induced IL-6 (inflammatory
cytokine), IL-12p40 (Th1 cytokine) production and
inhibited TARC (Th2 cytokine) production by LCs [82].
When stimulated with SEB alone, DCs secreted abun-
dant TNF-α and slight IL-12. However, IL-1β and IL-10
were undetectable in the culture medium. Concurrent
with this process, DCs also expressed significantly higher
HLA-DR and costimulatory molecules [83]. Although
DCs do not kill S. aureus directly, depletion of DCs in
CD11c- DTR transgenic mice resulted in increased bacter-
ial loads in kidneys and lungs, higher mortality, more
severe inflammatory injury and abolishment of IL-12
production. Nevertheless, adoptive transfer of either im-
mature or LPS-matured bone marrow-derived DCs into
normal BALB/c mice improved the capacity of these
animals to eliminate S. aureus bacteria in the lungs. In
addition, the impaired immunity of DC-depleted mice
to S. aureus can be recovered by using exogenous re-
combinant mouse IL-12 [84]. These studies suggest that
DCs preferentially induce Th1 immune response when
encountered with S. aureus or SEs, probably through
producing of IL-12, and then orchestrate innate and
adaptive immune responses to fight against S. aureus
infection.
In addition to SEs, DCs also react to other components
derived from S. aureus. Leukocidin (Luk), an exotoxin of S.
aureus is also capable of initiating the Th1-oriented im-
mune response. Inden et al. demonstrated that LukF was
the main mediator to induce IL-12p40 and TNF-α produc-
tion in DCs in a dose-dependent fashion. Using a TLR4-
deficient mutant mouse model, IL-12p40 production ofDCs triggered by LukF was found to be controlled by
TLR4 signaling [34]. In contrast to monocytes and
monocyte-derived macrophages which preferentially
prime modulatory IL-10 and weak IL-17 responses,
monocyte-derived DCs were found to produce mainly
IL-12 and IL-23, and initiate robust Th1/Th17 responses
after staphylococcal peptidoglycan stimulation via TLR2
signaling [85,86]. Additionally, DCs can also be activated
by lipoproteins of viable S. aureus through TLR2-MyD88
signaling and secret more IFN-γ and IL-17 in CD4+ T cells
to improve bacterial clearing and disease outcome [87].
However, DCs may also have a role in the worsening of
atopic dermatitis (AD) inflammation caused by secondary
S. aureus infection. Wash fluid from AD lesions with
secondary S. aureus infection induced DCs to secrete
proinflammatory cytokines including IL-1β, IL-6, IL-10
and TNF-α in a MyD88-dependent manner. Production
of these cytokines strongly correlated with wash fluid-
contained lipoteichoic acid (LTA) which is a known
microbial ligand derived from S. aureus for TLR2 activa-
tion [88,89]. Further study showed that staphylococcal
LTA and muramyl dipeptide, the minimal structural
unit of peptidoglycan with immunostimulating activity,
synergistically induced maturation of human DCs and
secretion of TNF-α and IL-12 p40 [90]. In order to
unravel the roles of different DC subsets in S. aureus
infection in detail, Jin and colleagues compared the
differences of CD16+ and BDCA3+ DCs, BDCA1+ DCs
treated with S. aureus. In contrast to CD16+ and
BDCA3+ DCs, BDCA1+ DCs expressed high levels of
TLR2 and scavenger receptor A (SR-A) which are
required for recognition of S. aureus and subsequent ac-
tivation of BDCA1+ DCs. Consistent with previous
studies, BDCA1+DCs engulfed S. aureus efficiently and
then dramatically upregulated expression of surface
markers, such as costimulatory molecules, MHC class I
and II molecules. Moreover, BDCA1+DCs also secreted
abundant proinflammatory cytokines and promoted
IFN-γ production in CD4 and CD8 T cells [91]. These
data indicate that DCs have a complicated role in S. aureus
infection. It is appropriate to speculate that distinct subsets
of DCs may fulfill different immune responses against S.
aureus infection. These differences may explain the
diverse outcomes of humans infected with S. aureus.
pDCs, in addition to their well established involvement
in the viral immune response [39], also take part in host
response to extracellular bacteria, including S. aureus.
Parcina et al. showed that IFN-α production of pDCs
triggered by S. aureus was independent of TLR2 and
specific for coagulase-positive staphylococci. The spe-
cificity of the pDCs response to S. aureus was mediated
by Ag-specific IgG and CD32. Blockade of TLR7/9
using inhibitory DNA oligonucleotides and chloroquine
abrogated S. aureus-induced pDC activation, indicating
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this process [92]. It is reported that pDCs are located in
tonsillar crypts and oro-nasopharyngeal epithelium, where
they may encounter extracellular bacteria including colo-
nized S. aureus. These pDCs do produce abundant IFN-α,
TNF-α, IL-6 and show upregulated CD86 expression
when activated by S. aureus [93]. However, some studies
reported that pDCs alone are unresponsive to extracellular
bacteria including S. aureus [94,95]. Further studies are
needed to clarify the function of pDCs during S. aureus
infection. Possible roles of DCs in S. aureus infection are
illustrated in Figure 2.
Strategies of S. aureus to affect DC function
Skin sections treated with SEA or exfoliative toxin lead
to significant depletion of LCs. Cholera and pertussis
toxin-sensitive GTP-binding proteins were found to be
involved in the LC depletion in response to SEA [96].
Muraille et al. demonstrated that APCs, a mixture of B
cells, macrophages and DCs, obtained from mice
injected 2 days earlier with SEB failed to stimulate an
alloreactive in vitro response. In spite of an increase in
spleen cellularity secondary to SEB injection, the abso-
lute and relative number of DCs was significantly de-
creased upon SEB-treatment. However, no significant
reduction was observed in splenic B cells and cells
expressing a typical macrophage phenotype [97]. FurtherFigure 2 Possible roles of DCs in S. aureus infection. S. aureus triggered
inducing protective immune responses against S.aureus as well as promoti
effector cells are involved in this process. Abbreviations: SA, S. aureus.study showed that DCs activated by SEB secreted high
levels of IL-2 but no IL-12p70 and drove polarization of
na?ve T cells into the Th2 subset. Using the TLR2 stably
transfected human embryonic kidney (HEK) 293 cells
and anti-TLR2 antibodies, the signaling involved in this
process was demonstrated to be triggered by the SEB-
TLR2 interaction [32]. SEB also promoted the expression
of T cell immunoglobulin mucin domain (TIM) 4 in hu-
man DCs. TIM4 expressed-DCs preferentially induced Th2
responses through the interaction of TIM4 and TIM1 [98].
Phenol-soluble modulin (PSM) peptide toxins are
strongly expressed in CA-MRSA and exert their function
on DCs through interacting with the formyl peptide re-
ceptor (FPR)2. During infection, PSMs, a virulence factor
of CA-MRSA, attracted DCs through interaction with
FPR2. PSMs treated-DCs showed impaired clathrin-
mediated endocytosis and reduced secretion of the pro-
inflammatory cytokines such as TNF, IL-12 and IL-6
while increased IL-10 secretion. The IL-10 producing-
DCs inhibited T-cell activation and T-cell priming towards
Th1 cells. Furthermore, they also induced IL-10 producing
Tregs in vitro [99]. In turn, Tregs can also provide DCs
with immune regulatory activity in mice unresponsive to
SEB through IFN-γ-independent CD152-mediated activa-
tion of tryptophan catabolism [100]. These results suggest
that S. aureus can also direct DCs to induce Th2 and Treg
cell responses but inhibit Th1 responses in certainDCs (cDCs and pDCs) secret a variety of cytokines which are vital in
ng inflammation. Th1, Th17 cells and cytokines produced by these
Figure 3 Possible strategies of S. aureus to affect DCs function. Several components of S. aureus may affect DCs function. Possible tactics
used by S. aureus include killing DC directly, inhibiting Th1 responses, inducing Th2 and Treg responses as well as IL-10-producing B cells. Abbreviations:
SEB, S. aureus enterotoxin B; TIM4, T cell immunoglobulin mucin domain (TIM) 4; LukAB, leukocidin A/B; PSMs, Phenol-soluble modulin; spA-SA, surface
protein A-bearing S. aureus.
Wu and Xu Journal of Translational Medicine 2014, 12:358 Page 6 of 9
http://www.translational-medicine.com/content/12/1/358conditions. However, the accurate mechanisms of DCs to
initiate different immune responses have not been deter-
mined currently.
Apart from its effect on DC function, S. aureus can
also directly kill DCs to avoid immune clearance.
Dumont et al. demonstrated that a novel styphylococcal
cytotoxin denoted leukocidin A/B (LukAB) was respon-
sible for cytotoxicity towards monoctye-derived DCs.
Although LukA and LukB alone have little effect on cell
viability, a combination of the purified recombinant
LukA and LukB potently kills DCs [65]. Additionally,
CCR5, a well-known HIV coreceptor has also been
confirmed as a receptor for the S. aureus leukotoxin ED.
Through its interaction with CCR5, leukotoxin ED se-
lectively kills CCR5+ T lymphocytes and myeloid cells
including monocyte-derived DCs in a CCR5-dependent
manner [101].
In vitro studies showed that bone marrow derived DCs
of TLR9-/- mice produced significantly decreased IFN-β
levels after incubation with S. aureus USA300 for 20
hours, compared to wildtype mice. However, TLR9-/-
mice exerted enhanced clearance of S. aureus from the
airways and lung tissue. Further analysis indicated that
TNF may be related to the control of S. aureus infection
because its level in BALF was reduced significantly in
infected TLR9-/- while the other proinflammatory cyto-
kines including IL-17, CXCL-10, KC, IL-6, and IFN-γ
were unchanged, compared to controls [102]. This is
consistent with the detrimental effect of TNF signaling
on S. aureus pulmonary infection [103]. Parcina andcolleagues showed that human pDCs activated by
surface protein A-bearing S. aureus were involved in
TLR9 signaling and mediated B cell proliferation and
Ig production. Cooperation of pDCs and B cells enhanced
B cell-derived IL-10 production of which was partially
dependent on TLR2-active lipoproteins, a hallmark of the
Staphylococcus species [104]. These results indicate that
S. aureus may exploit pDCs and their TLRs to establish B
cell-mediated immune tolerance to facilitate infection.
Possible strategies of S. aureus to affect DCs function are
delineated in Figure 3.
Summary
DCs are vital mediators in both innate and adaptive im-
mune responses. During infection, DCs sense various
pathogens through distinct PRRs and orchestrate dif-
ferent immune arms to defend against invading patho-
gens. However, pathogens such as S. aureus have also
evolved tactics to evade immune clearance by impairing
activation and function of DCs. It is important to further
illuminate the role of differing subsets of DCs upon S.
aureus infection, which may be instrumental in devel-
oping new therapeutic strategies for S. aureus infection,
especially the MRSA infection.
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